Table 2 Comparison of mortality and renal outcomes between patients with urological malignancy and no malignancy in both total and matched sample
Total sample | Matched sample | ||||||
|---|---|---|---|---|---|---|---|
Variable | Total (2637) | Urological malignancy (160) | No malignancy (2477) | p-Value | Urological malignancy (160) | No malignancy (480) | p-Value |
Follow up, months | 48 (25.5–79) | 40.6 (23.4–69.6) | 48.6 (25.6–79.5) | 0.02 | 41.3 (23.7–72.7) | 47.4 (25.8–77.8) | 0.22 |
All-cause mortality | 905 (34.3) | 70 (43.75) | 835 (33.7) | 0.01 | 70 (43.8) | 230 (47.9) | 0.36 |
1st Cause death (Malignancy) | 11/476 (2.3) | 11/40 (27.5) | 0/436 (0) | < 0.001a | 11/40 (27.5) | 0/111 | < 0.001a |
1st Cause death (CVD) | 179/476 (37.6) | 7/40 (17.5) | 172/436 (39.4) | 0.006 | 7/40 (17.5) | 53/111 (47.7) | < 0.001 |
1St Cause death (Infection) | 142/476 (29.8) | 10/40 (25) | 132/436 (30.3) | 0.49 | 10/40 (25) | 29/111 (26.1) | 0.89 |
1st Cause death (ESRD) | 55/476 (11.6) | 4/40 (10) | 51/436 (11.7) | 1.00a | 4/40 (10) | 9/111 (8.1) | 0.75a |
Age at death, years | 78.7 (72–84.4) | 79.4 (73–83.8) | 78.6 (72–84.4) | 0.50 | 78.8 (72.9–83.7) | 79.4 (74.5–83.6) | 0.56 |
ESRD | 777 (29.5) | 45 (28.1) | 732 (29.5) | 0.70 | 45 (28.1) | 131 (27.3) | 0.84 |
RRT | 568 (21.5) | 28 (17.5) | 540 (21.8) | 0.20 | 28 (17.7) | 72 (15) | 0.45 |
NFCVE | 251 (9.5) | 17 (10.6) | 234 (9.4) | 0.24 | 17 (10.6) | 59 (12.29) | 0.57 |
Rate of decline of eGFR (eGFR slope) mL/min/1.73m2/year | −1.05 (−2.5 to 0.52) | −1.25 (−3.27 to 0.51) | 0.31 | −1.05 (−2.5 to 0.52) | −0.88 (− 2.3 to 0.61) | 0.58 |